]>
IRCT20251112067972N1 IRCT 2026-04-23 vice chancellor for research and technology The effect of colchicine in patients with covid 19 The effectiveness of colchicine in the incidence of pulmonary complications after COVID-19 infection: a randomized clinical trial 2026-01-26 anticipated 100 Complete https://irct.ir/trial/87420 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The method of randomization will be that by using the table of random numbers created on the online site, the patients will be assigned to 2 groups and the method of allocation will be using envelopes in bed. 3 COVID-19 disease. Intervention 1: Intervention group: In the intervention group, after recovering from the acute phase, they will receive colchicine 0.5 mg twice a day for a period of one month. After the 3-month period, lung CT scan will be performed to investigate post-covid pulmonary complications, and the variables of pulmonary fibrosis, cavitary lesions, bronchitis, bronchiectasis and air trapping lesions will be evaluated and quantitatively compared in terms of the number of involved lobes in both groups. Intervention 2: Control group: In the control group, after recovering from the acute phase, they will receive placebo twice a day for a period of one month. After the 3-month period, lung CT scan will be performed to investigate post-covid pulmonary complications, and the variables of pulmonary fibrosis, cavitary lesions, bronchitis, bronchiectasis and air trapping lesions will be evaluated and quantitatively compared in terms of the number of involved lobes in both groups. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information
public Fateme Alizadeh moosavi
Vasei hospital; touhid shahr blvd;sabzevar town
Sabzevar Iran (Islamic Republic of) 9613873137 +98 51 4465 1300 AlizademoosaviF01@medsab.ac.ir Sabzevar University of Medical Sciences scientific Fateme Alizadeh moosavi
Vasei hospital; touhid shahr blvd;sabzevar town
Sabzevar Iran (Islamic Republic of) 9613873137 +98 51 4465 1300 AlizademoosaviF01@medsab.ac.ir Sabzevar University of Medical Sciences Iran (Islamic Republic of) Patients who have been clinically, radiologically and PCR confirmed to have COVID-19 Age above 18 years Informed written consent 18 years no limit Both History of hypersensitivity to colchicine Pregnancy or lactation Patients with severe renal impairment (creatinine clearance [CrCl] < 30 mL/min) Patients with severe hepatic impairment (AST or ALT > 5 times the upper limit of normal [ULN]) Patients with hematologic dyscrasias, absolute neutrophil count < 1,000/mm³ or platelet count < 50,000/mm³ Patients with a history of severe heart failure Severe diarrhea, diverticulitis, or bowel perforation Patients unable to tolerate oral intake Patient demise Concomitant use of medications with contraindications to colchicine U07.1+J12. COVID-19, virus identified /Other viral pneumonia Treatment - Drugs Placebo Intervention group: In the intervention group, after recovering from the acute phase, they will receive colchicine 0.5 mg twice a day for a period of one month. After the 3-month period, lung CT scan will be performed to investigate post-covid pulmonary complications, and the variables of pulmonary fibrosis, cavitary lesions, bronchitis, bronchiectasis and air trapping lesions will be evaluated and quantitatively compared in terms of the number of involved lobes in both groups. Control group: In the control group, after recovering from the acute phase, they will receive placebo twice a day for a period of one month. After the 3-month period, lung CT scan will be performed to investigate post-covid pulmonary complications, and the variables of pulmonary fibrosis, cavitary lesions, bronchitis, bronchiectasis and air trapping lesions will be evaluated and quantitatively compared in terms of the number of involved lobes in both groups. Investigating changes in pulmonary fibrosis in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan. Investigating changes in pulmonary bronchiectasis in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan. Investigating changes in bronchitis in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan. Investigating changes in cavitary lesions and air retention in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan. Investigating changes in air retention in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan. vice chancellor for research and technology Approved 2025-03-09 Ethics committee of sabzevar University of Medical Sciences Sabzevar, Shohadaye Hasteiee Boulevard, Sabzevar University of Medical Science Sabzevar Razavi Khorasan Iran (Islamic Republic of)